Scancell to Bolster Cash by $10M, Advance Moditope Work
By Nuala Moran
Tuesday, July 9, 2013
LONDON Cancer immunotherapy specialist Scancell Holdings plc is looking to raise £6.5 million (US$9.7 million) in a placing and open offer, allowing it to expand an ongoing Phase I/II trial of its lead Immunobody product, SCIB1, and to commence preclinical development of a second cancer vaccine platform, Moditope.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.